Alkermes's major customers
McKesson accounted for 31% of Alkermes's revenue in FY 2025, up from 25% a year earlier.
Get an email when Alkermes's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Alkermes
Customers that Alkermes named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| McKessonMCK | 31% | ▲ from 25% | 6 years | FY 2025 · filed 25 Feb 2026 |
| Cencora Incorporation | 20% | ▲ from 15% | 4 years | FY 2025 · filed 25 Feb 2026 |
| Cardinal HealthCAH | 17% | from 19% | 7 years | FY 2025 · filed 25 Feb 2026 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Janssen | 17% | last FY 2024 | 12 years | FY 2024 · filed 25 Feb 2026 |
| Acorda | 13% | last FY 2017 | 5 years | FY 2017 · filed 16 Feb 2018 |
| AmerisourceBergen | 12% | last FY 2023 | 4 years | FY 2023 · filed 21 Feb 2024 |
| BiogenBIIB | 11% | last FY 2024 | 6 years | FY 2024 · filed 25 Feb 2026 |
| Acorda Therapeutics | 10% | last FY 2018 | 3 years | FY 2018 · filed 11 Feb 2021 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API